##common.pageHeaderLogo.altText##
DOI:
https://doi.org/10.57187/5030

Medical guidelines

Vol. 156 No. 9 (2026)

Desmopressin (DDAVP): indications and practicalities

Cite this as:
Swiss Med Wkly. 2026;156:5030
Published
30.09.2026

Summary

BACKGROUND: Desmopressin (1-deamino-8-D-arginine vasopressin, or DDAVP) is available in Switzerland for the treatment of non-severe haemophilia A and von Willebrand disease.

OBJECTIVE: To provide practical guidance for the use of desmopressin in patients with non-severe haemophilia A, von Willebrand disease, bleeding disorders of unknown cause and mild platelet function disorders.

METHODS: Based on the available literature and clinical experience in Switzerland, the Swiss Society of Haematology’s Haemostasis Working Group and the Swiss Haemophilia Network worked together to reach a consensus on the use of desmopressin.

RESULTS AND CONCLUSIONS: Desmopressin may increase and normalise factor VIII and von Willebrand factor levels in patients with non-severe haemophilia A and von Willebrand disease and can prevent or treat bleeding in patients with bleeding disorders of unknown cause and mild platelet function disorders. A desmopressin trial is recommended to verify tolerability and identify responders, as the response to the drug is not predictable based on baseline levels of factor VIII and von Willebrand factor. Previously observed side effects and current contraindications must be carefully evaluated prior to every administration.

References

  1. 1. Mannucci PM. Enhancement of fibrinolysis by vasopressin and adrenaline: a role for cyclic AMP?. Thromb Res. 1974;4:539.
  2. 2. Barnhart MI, Chen S, Lusher JM. DDAVP: Does the drug have a direct effect on the vessel wall. Thromb Res. 1983;31:239.
  3. 3. Sakariassen KS, Cattaneo M, van der Berg A, Ruggeri ZM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood. 1984;64:229.
  4. 4. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 2003;1:682-689.
  5. 5. Cattaneo M. Desmopressin in the treatment of patients with defects of platelet function. Haematologica. 2002;87:1122-1124.
  6. 6. Colucci G, Stutz M, Rochat S, Conte T, Pavicic M, Reusser M, et al. The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. Blood. 2014;103:1905-1916.
  7. 7. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of Plasminogen Activator and factor VIII increase after vasoactive drugs. Br J Haemat. 1975;30:81-93.
  8. 8. Mannucci PM, Ruggeri ZM, Pareti F, Capitanio A. 1-Deamino-8-D-Arginine Vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. The Lancet. 1977;1:689; 869-872.
  9. 9. Mannucci PM. Desmopressin (DDAVP) for treatment of disorders of hemostasis. In: Progress in Hemostasis and Thrombosis. 1986;8:19-45.
  10. 10. Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood. 1989;74:1997-2000.
  11. 11. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the Management of Hemophilia. Haemophilia. 2020;26(Suppl 6):1-158.
  12. 12. Connell NT, Flood VH, Brignardello-Petersen R, Abdul-Kadir R, Arapshian A, Couper S, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5:301-325.
  13. 13. Rodeghiero F, Ghiotto L, Pontalto L, Casini A, Castaman G, Abdul-Kadir R, et al. Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: back to the clinical phenotype. HemaSphere. 2025;9:e70111.
  14. 14. Loomans JI, Kruip MJHA, Carcao M, Jackson S, van Velzen AS, Peters M, et al. Haematologica. 2018;103:550-557.
  15. 15. Zwagemaker AF, Kloosterman FR, Coppens M, Gouw SC, Boyce S, Bagot CN, et al. Desmopressin for bleeding in non-severe hemophilia A: suboptimal use in a real-world setting. Res Pract Thromb Haemost. 2022;6:e12777.
  16. 16. Seaman CD. Efficacy of adjusted weight-based dosing of desmopressin (1-deamino-8-d-arginine vasopressin in type 1 von Willebrand disease. Blood Coagul Fibrinolysis. 2023;34:462-464.
  17. 17. Mannucci PM, Vicente V, Alberca I, Sacchi E, Longo G, Harris AS, et al. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost. 1987;58:1037-1039.
  18. 18. Laan S, Del Castillo Alvareyy J, Cannegieter S, Fijnvandraat K, Kruip M, le Cessie S, et al. DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis. Blood. 2025;154:1814-1825.
  19. 19. Sharthkumar A, Grreist A, Di Paola J, Winay J, Roberson C, Heiman M, et al. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease. Haemophilia. 2008 May;14(3):539-548. doi:10.1111/j.1365-2516.2008.01666.x
  20. 20. Leissinger C, Carcao M, Gill JC, Journeycake J, Singleton T, Valentino L. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. Haemophilia. 2014;20:158-167.
  21. 21. Revel-Vilk S, Blanchette VS, Sparling C, Stain AM. DDAVP challenge tests in boys with mild/moderate haemophilia A. Br J Haemat. 2002;117:947-951.
  22. 22. Kobrinsky NL, Israels ED, Gerrard JM, Cheang MS, Watson CM, Bishop AJ, et al. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet. 1984;1:1145-1148.
  23. 23. Schulman S, Johnsson H, Egberg N, Blombäck M. DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb Res. 1987;45:165-174.
  24. 24. Cattaneo M, Pareti FI, Zighetti M, Lecchi A, Lombardi R, Mannucci PM. Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time. J Lab Clin Med. 1995;125:540-547.
  25. 25. Coppola A, Di Minno G. Desmopressin in inherited disorders of platelet function. Haemophilia. 2008;14(suppl 1):31-39.
  26. 26. Bolton-Maggs PHB, Chalmers EA, Collins PW, Harrison P, Kitchem S, Liesner RJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haemat. 2006;135:603–633.
  27. 27. Baker RI, Choi P, Curry N, Gebhart J, Gomez K, Henskens Y, et al. Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH. J Thromb Haemost. 2024;22:2059-2070.
  28. 28. Menegatti M, Biguzzi E, Peyvandi F. Management of rare acquired bleeding disorders. Hematology Am Soc Hematol Educ Program. 2019;2019:80-87.
  29. 29. Castaman G. Desmopressin for the treatment of haemophilia. Haemophilia. 2008;14(Suppl 1):15-20.
  30. 30. Biguzzi E, Siboni SM, Peyvandi F. Acquired Von Willebrand syndrome and response to desmopressin. Haemophilia. 2018;24:e25-e28.
  31. 31. Mast KJ, Nunes ME, Ruymann FB, Kerlin BA. Desmopressin responsiveness in children with Ehler-Danlos syndrome associated bleeding symptoms. Br J Haematol. 2009;144:230-233.
  32. 32. Grant O, Mulligan K, Donnelly J, Ní Áinle F, Mhuircheartaigh RN. Management of hemorrhage during cesarean delivery in a patient withvascular Ehlers-Danlos syndrome: a case report. A A Pract. 2023 Jan 11;17(1):e01655.
  33. 33. Available from: https://www.orphananesthesia.eu/en/rare-diseases/published-guidelines/ehlers%E2%80%93danlos-syndrome/1712-ehlers-danlos-syndrome-3/file.html
  34. 34. Ruzicka H, Björkman S, Lethagen S, Sterner G. Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure. Pharmacol Toxicol. 2003;92:137-42.
  35. 35. Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009;113:526-534.
  36. 36. Guillet B, Pawlowski M, Boisseau P, Répessé Y, Beurrier P, Bayart S, et al. Genotype-Dependent Response to Desmopressin in Hemophilia A and Proposal of a Predictive Response Score. Thromb Haemost. 2024;124:922-936.
  37. 37. James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5:280-300.
  38. 38. Mazurier C, Gaucher C, Jorieux S, Goudeman M. Biological effect of desmopressin in eight patients with type 2n ('Normandy') von Willebrand disease. Br J Haematol. 1994;88:849-854.
  39. 39. Castaman G, Mancuso ME, Giacomelli SH, Tosetto A, Santagostino E, Mannucci PM, et al. Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A. J Thromb Haemost. 2009;7:1824-1831.
  40. 40. Connell NT, James PD, Brignardello-Petersen R, Abdul-Kadir R, Ameer B, Arapshian A, et al. von Willebrand disease: proposing definitions for future research. Blood Adv. 2021;5:565-569.
  41. 41. Romano LGR, Schütte LM, van Hest RM, Meijer K, Laros-van Gorkom BAP, Nieuwenhuizen L, et al. Peri-operative desmopressin combined with pharmacokinetic-guided factor VIII concentrate in non-severe haemophilia A patients. Haemophilia. 2024;30:355-366.
  42. 42. Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII‐deficient women. Blood. 2005;105:3382.
  43. 43. Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia. 2012;18:25-33.
  44. 44. Castaman G, James PD. Pregnancy and delivery in women with von Willebrand disease. Eur J Haematol. 2019;103:73-79.
  45. 45. Platton S, Baker P, Bowyer A, Keenan C, Lawrence C, Lester W, et al. Guideline for laboratory diagnosis and monitoring of von Willebrand disease: A joint guideline from the United Kingdom Haemophilia Centre Doctors' Organisation and the British Society for Haematology. Br J Haematol. 2024;204:1714-1731.

Most read articles by the same author(s)

1 2 > >>